10:07 AM EDT, 10/09/2024 (MT Newswires) -- Longeveron ( LGVN ) said Wednesday that its submission titled "Long-term Transplant-free Survival Is Improved In Hypoplastic Left Heart Syndrome With Cell-based Therapy" was selected for presentation at the annual Congenital Heart Surgeons' Society meeting to be held in Chicago starting Oct. 27.

The presentation will feature 5-year survival data from the ELPIS I follow-on study, Longeveron ( LGVN ) Chief Executive Wa'el Hashad said, adding that Longeveron ( LGVN ) is currently evaluating the company's Lomecel-BTM cellular therapy in a phase 2b trial as a potential adjunct therapy for treating hypoplastic left heart syndrome.

Longeveron ( LGVN ) shares were down 2.2% in early trading.

Price: 1.80, Change: -0.04, Percent Change: -2.17